日本薬理学雑誌
Online ISSN : 1347-8397
Print ISSN : 0015-5691
ISSN-L : 0015-5691
特集 多様なライフステージにおける精神疾患発症に関わる環境因子とその創薬標的としての可能性
加齢に伴う認知機能障害を標的とした薬物治療戦略
Ming Teng Koh
著者情報
ジャーナル オープンアクセス

2012 年 139 巻 4 号 p. 157-159

詳細
抄録

Amnestic mild cognitive impairment (aMCI) is associated with increased activation in the CA3-dentate region of hippocampus. Excess CA3 activity also occurs in aged rats with memory impairment. Therapies to counter such excess activity might include antiepileptics or agonists for GABAA α5 receptors, which regulate tonic inhibition. Use of GABAA α5 agonists may seem unexpected because GABAA α5 inverse agonists were developed as cognitive enhancers. We found that inverse agonists, while yielding benefit in normal young adult rats, are not effective in treating memory loss in aged rats. Instead, aged rats showed improved memory after treatment with selective GABAA α5 agonists and with certain antiepileptics. These benefits of treatment are consistent with the concept that excess activity in the CA3 of the hippocampus is a dysfunctional condition contributing to age-associated memory impairment. Because excess hippocampal activation is also observed in aMCI, our findings support the use of antiepileptic or GABAA α5 agonist therapy in aMCI. Such therapy, in addition to memory improvement, may also have disease modifying potential because hippocampal overactivity in aging/MCI predicts further cognitive decline and conversion to Alzheimer’s disease.

著者関連情報
© 2012 公益社団法人 日本薬理学会
前の記事 次の記事
feedback
Top